このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

2026年10月12日 更新者:AbbVie

A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination in Adult Subjects With Ovarian Cancer

Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer.

ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has 6 parts where participants will receive ABBV-901, alone or in combination with other anticancer therapies. Around 285 participants will be enrolled in the study at approximately 45 sites around the world.

In part 1, participants will receive escalating doses of intravenous (IV) ABBV-901 alone. In part 2, participants will receive 1 of 3 doses of IV ABBV-901 alone to determine the optimized dose. In part 3, participants will receive escalating doses of IV ABBV-901 in combination with IV bevacizumab. In part 4, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV bevacizumab. in Part 5, participants will receive escalating doses of IV ABBV-901 in combination with IV carboplatin and IV bevacizumab and in part 6, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV carboplatin and IV bevacizumab. The total study duration will be approximately 3 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

調査の概要

研究の種類

介入

入学 (推定)

285

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • California
      • Duarte、California、アメリカ、91010
        • 募集
        • City of Hope National Medical Center /ID# 281381
      • Irvine、California、アメリカ、92618
        • 募集
        • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 280914
    • Colorado
      • Denver、Colorado、アメリカ、80218
        • 募集
        • Sarah Cannon Research Institute at HealthONE /ID# 278785
    • Illinois
      • Chicago、Illinois、アメリカ、60637
        • 募集
        • University of Chicago Medical Center /ID# 278295
    • Nebraska
      • Omaha、Nebraska、アメリカ、68198
        • 募集
        • University Of Nebraska Medical Center /ID# 281020
    • Texas
      • San Antonio、Texas、アメリカ、78229
        • 募集
        • NEXT Oncology - San Antonio /ID# 278606
    • Utah
      • West Valley City、Utah、アメリカ、84119
        • 募集
        • Start Mountain Region /ID# 278609
    • Virginia
      • Fairfax、Virginia、アメリカ、22031
        • 募集
        • Next Virginia /ID# 278607
      • Haifa、イスラエル、3109601
        • 募集
        • Rambam Health Care Campus /ID# 278418
      • Jerusalem、イスラエル、91120
        • 募集
        • Hadassah Medical Center-Hebrew University /ID# 278420
    • Tel Aviv
      • Ramat Gan、Tel Aviv、イスラエル、5265601
        • 募集
        • The Chaim Sheba Medical Center /ID# 278416
    • New South Wales
      • Blacktown、New South Wales、オーストラリア、2148
        • 募集
        • Blacktown Hospital /ID# 282426
    • Victoria
      • Clayton、Victoria、オーストラリア、3168
        • 募集
        • Monash Health - Monash Medical Centre - Clayton /ID# 281468
      • Melbourne、Victoria、オーストラリア、3000
        • 募集
        • Peter MacCallum Cancer Centre. /ID# 281751
      • Barcelona、スペイン、08035
        • 募集
        • Hospital Universitari Vall d Hebron /ID# 280442
      • Madrid、スペイン、28040
        • 募集
        • Hospital Universitario Fundacion Jimenez Diaz /ID# 280440
      • Madrid、スペイン、28050
        • 募集
        • Hospital Universitario HM Sanchinarro /ID# 280439
    • Madrid
      • Majadahonda、Madrid、スペイン、28222
        • 募集
        • Hospital Universitario Puerta de Hierro - Majadahonda /ID# 280459
    • Pays de la Loire Region
      • Saint-Herblain、Pays de la Loire Region、フランス、44805
        • 募集
        • Institut De Cancerologie De L'Ouest - Site Rene Gauducheau /ID# 280684
    • Rhone
      • Lyon、Rhone、フランス、69373
        • 募集
        • Centre Leon Berard /ID# 280575
      • Lisbon、ポルトガル、1649-035
        • 募集
        • Unidade Local de Saude de Santa Maria /ID# 280296
      • Porto、ポルトガル、4200-072
        • 募集
        • Instituto Portugues de Oncologia do Porto Francisco Gentil /ID# 280293
      • Taipei、台湾、112
        • 募集
        • Taipei Veterans General Hospital /ID# 281349
      • Taipei、台湾、100
        • 募集
        • National Taiwan University Hospital /ID# 280701
    • Chiba
      • Kashiwa-shi、Chiba、日本、277-8577
        • 募集
        • National Cancer Center Hospital East /ID# 278604
    • Saitama
      • Hidaka、Saitama、日本、350-1298
        • 募集
        • Saitama Medical University International Medical Center /ID# 278437
    • Shizuoka
      • Sunto-gun、Shizuoka、日本、411-8777
        • 募集
        • Shizuoka Cancer Center /ID# 278538

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Diagnosis of an advanced or unresectable malignant high grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), fallopian tube or primary peritoneal cancer by histology (World Health Organization [WHO] criteria).
  • Participants enrolled in backfill (Part 1) must provide consent to paired fresh biopsies which are pretreatment and on-treatment tumor biopsies from the same tumor lesion.

For Parts 1-4:

- Participants must be considered platinum resistant or platinum ineligible. Platinum resistant disease is defined as radiographic progression within 6 months (up to 182 days) after the last dose of the most recent platinum therapy).

For Parts 5-6:

- Participants will have platinum-sensitive disease defined as radiographic progression > 6 months from last dose of platinum-based chemotherapy. Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression.

Exclusion Criteria:

  • Ovarian Cancer (OC) with histologies other than high grade serous OC including endometrioid, low grade, mucinous, carcinosarcoma or sarcomatous histology, mixed tumors or low grade/borderline ovarian tumor.
  • Participants with platinum refractory disease.
  • Prior therapy with an antibody-drug conjugate containing a topoisomerase inhibitor.
  • Prior history of Grade >= 2 interstitial lung disease (ILD) or pneumonitis.
  • Prior history of Grade 2 >= 2 ILD or pneumonitis or any evidence of active ILD or pneumonitis on Screening chest computed tomography (CT) scan.

For Parts 3-6:

  • History of Grade 3/4 adverse events that, in the opinion of the investigator, are attributed to bevacizumab.
  • History of clinically significant cardiac disease including CHF Class II or higher NYHA; active coronary artery disease, MI within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted).
  • Echocardiogram with ejection fraction <= 50% and no other clinically significant cardiac abnormalities that in the opinion of the investigator, would increase the participants susceptibility to cardiac toxicity.

For Parts 5-6:

- Participants who had prior allergic reaction to platinum containing compound.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Part 1: ABBV-901 Dose Escalation

Participants will receive escalating doses of ABBV-901 alone, as part of the approximately 3 year study duration.

Intravenous (IV)

実験的:Part 2: ABBV-901 Optimization Dose A

Participants will receive ABBV-901 dose A alone, as part of the approximately 3 year study duration.

Intravenous (IV)

実験的:Part 2: ABBV-901 Optimization Dose B

Participants will receive ABBV-901 dose B alone, as part of the approximately 3 year study duration.

Intravenous (IV)

実験的:Part 2: ABBV-901 Optimization Dose C

Participants will receive ABBV-901 dose C alone, as part of the approximately 3 year study duration.

Intravenous (IV)

実験的:Part 3: ABBV-901 + Bevacizumab Escalation

Participants will receive escalating doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

実験的:Part 4: ABBV-901 + Bevacizumab Expansion

Participants will receive the recommended doses for expansion doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

実験的:Part 5: ABBV-901 + Carboplatin + Bevacizumab Escalation

Participants will receive escalating doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Intravenous (IV)

実験的:Part 6: ABBV-901 + Carboplatin + Bevacizumab Expansion

Participants will receive the recommended doses for expansion doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Intravenous (IV)

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants with Adverse Events (AE)
時間枠:Up to Approximately 3 Years

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment.

Up to Approximately 3 Years
Overall Response (as assessed by the investigator)
時間枠:Up to Approximately 3 Years

Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by the investigator.

Up to Approximately 3 Years

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall Response (as assessed by independent central review)
時間枠:Up to Approximately 3 Years

Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by independent central review (ICR).

Up to Approximately 3 Years
Duration of Response (DOR)
時間枠:Up to Approximately 3 Years

DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to RECIST Version 1.1 criteria to disease progression or death of any cause, whichever occurs earlier.

Up to Approximately 3 Years
Progression-free survival (PFS)
時間枠:Up to Approximately 3 Years

PFS is defined as time from first study treatment to a documented disease progression according to RECIST Version 1.1 (or other assessment criteria), as determined by the investigator, or death due to any cause, whichever occurs earlier.

Up to Approximately 3 Years
Overall Survival (OS)
時間枠:Up to Approximately 3 Years

OS is defined as time from first study treatment to death due to any cause.

Up to Approximately 3 Years
Disease Control Rate
時間枠:Up to Approximately 3 Years

Disease Control Rate is defined as the percentage of participants with best overall response (BOR) of stable disease (SD), PR or better per investigator review according to RECIST version 1.1 criteria.

Up to Approximately 3 Years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:ABBVIE INC.、AbbVie

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年11月27日

一次修了 (推定)

2028年12月1日

研究の完了 (推定)

2029年1月1日

試験登録日

最初に提出

2025年12月2日

QC基準を満たした最初の提出物

2025年12月2日

最初の投稿 (実際)

2025年12月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月13日

QC基準を満たした最後の更新が送信されました

2026年10月12日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する